Celldex Therapeutics Inc.
CLDX
Market Cap$1.21B
Close$
$-1.28
106.6% downside
Current Fair Value
106.6% downsideOvervalued by 106.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.21 Billion |
|---|---|
| Enterprise Value | $1.19 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-2.45 |
| Beta | 1.59 |
| Outstanding Shares | 64,395,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -7.46 |
|---|---|
| PEG | -73.97 |
| Price to Sales | - |
| Price to Book Ratio | 1.76 |
| Enterprise Value to Revenue | 119.31 |
| Enterprise Value to EBIT | -7.74 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Celldex Therapeutics Inc.
CEO: Anthony Marucci Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeu...